• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

ASCRS 2023: Atia Vision presenting clinical data on IOL system

Article

According to the company, outcomes show the potential for its modular, shape changing lens system.

a close image of a doctor holding an IOL device. (Image Credit: AdobeStock/Oktay)

(Image Credit: AdobeStock/Oktay)

Atia Vision Inc. announced the first clinical data about their patented OmniVu IOL System will be presented at the American Society of Cataract and Refractive Surgery’s annual meeting in San Diego, California.

According to the company, its first-in-human findings will be shared by George O. Waring IV , MD, founder and medical director of the Waring Vision Institute in South Carolina, from 3:40 to 3:45 p.m. PT on Saturday. His presentation, which will take place in Upper-Level Room 5B in the San Diego Conference Center, is titled " Prospective, Open-Label, Non-Randomized, Trial of a Presbyopia-Correcting, Modular Intraocular Lens System for Treatment of Cataract. "

"There has long been an unmet need for a solution that reliably delivers a full range of vision to patients with cataracts and presbyopia without visual disturbances," Waring said in the news release. "I am extremely encouraged by these early findings and look forward to the results of additional studies."

With this lens, Atia Vision aims to address the limitations of current solutions for cataracts, which affect nearly 65 million people worldwide and can lead to blindness if untreated. Implanted using conventional techniques, the novel IOL features a fluid-filled, shape-changing base designed to provide clear vision from far to near and a fixed-power front optic that allows physicians to select the appropriate lens to meet each patient's target refraction.

The OmniVu Lens System is designed to predictably, consistently, and reproducibly restore full functional visual acuity, mimicking the eye's natural ability at near, intermediate, and distance ranges without generating side effects such as halos, glares, or artifacts. In developing the lens, Atia Vision evaluated and leveraged the comprehensive body of research conducted in the accommodative lens arena to date.

"We are extremely pleased with these early clinical findings related to the performance of our next-generation lens," Mariam Maghribi, president and CEO of Atia Vision, said in the news release. "We are excited about the possibilities this innovative technology may offer to eye care professionals and their patients seeking an alternative solution for cataract surgery that facilities a full range of vision."

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.